Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer TCR therapeutics - MiNK Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: anticancer TCR therapeutics - MiNK Therapeutics

Latest Information Update: 16 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MiNK Therapeutics
  • Developer ImmunoScape; MiNK Therapeutics
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 20 Dec 2023 MiNK Therapeutics and Immunoscape agree to co-develop T-cell receptor therapeutics for Solid tumours and Haematological malignancies
  • 20 Dec 2023 Early research in Haematological malignancies in USA (Parenteral) before December 2023
  • 20 Dec 2023 Early research in Solid tumours in USA (Parenteral) before December 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top